Oslo, Norway, 23 June 2026 – AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, is pleased to announce the publication of the Phase I clinical study evaluating APC148, AdjuTec Pharma's novel metallo-β-lactamase (MBL) inhibitor, in healthy volunteers.
The study, titled "Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers", has been published in Antimicrobial Agents and Chemotherapy.
The Phase I trial assessed the safety, tolerability, and pharmacokinetic profile of APC148 in healthy participants through a dose-escalation design. The results demonstrated that APC148 was well tolerated and supported its continued clinical development as a potential solution to combat antibiotic-resistant bacterial infections caused by MBL-producing pathogens.
The publication represents an important milestone in the development of APC148 and further strengthens the scientific foundation of AdjuTec Pharma's mission to address the growing global threat of antimicrobial resistance.
The full publication is available HERE
We would like to thank the study participants, investigators, clinical partners, and the entire AdjuTec Pharma team for their contribution to this achievement.
About antimicrobial resistance (AMR)
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
About AdjuTec Pharma AS
AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company´s technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The company is located at ShareLab(Oslo Science Park), Gaustadalléen 21 - downtown Oslo.
For more information, please visit www.adjutecpharma.com or contact us at info@adjutecpharma.com
The study, titled "Phase I dose-ascending, safety, and pharmacokinetics study of APC148, a novel metallo-β-lactamase inhibitor, in healthy volunteers", has been published in Antimicrobial Agents and Chemotherapy.
The Phase I trial assessed the safety, tolerability, and pharmacokinetic profile of APC148 in healthy participants through a dose-escalation design. The results demonstrated that APC148 was well tolerated and supported its continued clinical development as a potential solution to combat antibiotic-resistant bacterial infections caused by MBL-producing pathogens.
The publication represents an important milestone in the development of APC148 and further strengthens the scientific foundation of AdjuTec Pharma's mission to address the growing global threat of antimicrobial resistance.
The full publication is available HERE
We would like to thank the study participants, investigators, clinical partners, and the entire AdjuTec Pharma team for their contribution to this achievement.
About antimicrobial resistance (AMR)
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
About AdjuTec Pharma AS
AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company´s technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The company is located at ShareLab(Oslo Science Park), Gaustadalléen 21 - downtown Oslo.
For more information, please visit www.adjutecpharma.com or contact us at info@adjutecpharma.com